Budget Impact Analysis of Discontinuing Tyrosin Kinase Inhibitors in Patients With Chronic Myeloid Leukemia Achieving a Complete Molecular Response by Using Probabilistic Markov Approach

Inclusion Criteria

• •Study period between 01/01/2005 and 12/31/2015 (cf. figure) including:
• •Inclusion period: 01/01/2008 to 12/31/2014;
• •Date of inclusion: date of the last TKI reimbursement before discontinuation which will be defined by the absence of any TKI reimbursement without the occurrence of death during at least 61 days following the 30-day coverage period of a TKI reimbursement;
• •History: 3-year period;
• •Follow-up: at least 1 year after inclusion or until death whatever occurs first.
• •Patients aged 18 years or over;
• •Patients with LTD registration or hospitalization for CML (primary, associated and linked ICD-10 diagnosis code, i.e. C92.1 or C921) during the study period;
• •Patients who discontinued their TKI treatment for the first time during the inclusion period;
• •Patients treated with TKI during the inclusion period with a minimum of 3 year-period of TKI regular treatment before TKI discontinuation. A 3 year-period of TKI regular treatment will be defined on the presence of at least 10 TKI reimbursements per year during the 3 years preceding TKI discontinuation.